The Critical Missing Piece of the Due Diligence Process
Organizations are rapidly pursuing mergers and acquisitions of hospitals, physician practices, and other services to promote competitive strength and enlarge service offerings. The resultant due diligence process must be swift and thorough.
The issue of assessing clinical regulatory compliance with the Centers for Medicare and Medicaid Services (CMS) Conditions of Participation is frequently overlooked or assumed to be a lower priority. Unknown risks and poor practices may crop up alongside what would otherwise be a good strategic investment.
When acquiring a new facility, healthcare organizations must ensure an extra margin of safety; this can be achieved through a clinical regulatory compliance due diligence assessment.
Clinical Regulatory Compliance Due Diligence Assessments
Compass performs clinical due diligence to provide health systems with knowledge and awareness about compliance risks that may accompany an acquisition, including careful attention to triggers for additional scrutiny from CMS.
Staffed by a team of expert clinician consultants, the assessment will be tailored to each client’s specific needs and concerns, such as the environment of care, or concerns about clinical operations and equipment, or a history of lapsed compliance with patient care requirements such as infection control, staffing levels, or staff competence.
As a result, our approach provides an objective assessment of compliance, revealing vulnerabilities and risks that require attention and resources for remediation.
Healthcare systems that are contemplating acquisitions have found that our clinical assessments facilitated their ability to assess potential transactions in terms of effort needed to attain or maintain compliance with and, therefore, certification in the Medicare program, and aided in their decisions with regards to moving forward with the acquisitions.
For more information about clinical regulatory compliance due diligence assessments from Compass Clinical Consulting, contact Kate Fenner, RN, PhD, CEO and Managing Director, or Mark Reifsteck, MHA, FACHE, Managing Director, at 513.241.0142, contact our office, or fill out the form below.